Drs Harrington and Hernandez discuss the inefficiencies of the US clinical trial system and their involvement in the National Patient-Centered Clinical Research Network's first trial on aspirin dose.

Dr Jacobs discusses a new therapeutic class of agents for migraine prevention and some phase 2 results.

Dr Amy Pollak talks to Dr William Haley of the Mayo Clinic about how to interpret the results from the SPRINT trial and why practitioners should stay tuned for further results.

Are declining PSA screening rates placing men at risk? Dr Chodak discusses the latest opinions for and against routine screening.

Past AACR president Dr Carlos Arteaga describes translational studies and emerging therapies that are transforming the clinical practice of breast cancer.

New findings from the UK show multimodal ovarian cancer screening to be highly effective in reducing mortality, but Dr Andrew Kaunitz urges clinicians to await guidelines for routine screening.

'Whatever it takes,' says Dr Jeffrey Berns, we need to get patients with advanced kidney disease into the care of a nephrologist before dialysis is initiated to reduce mortality during the first year.

Regional variation in therapeutic decision-making and clinical practice prompts Dr O'Donoghue to question what affects her choices.

Dr JoAnn Manson urges clinicians to consider physical activity as a 'vital sign.'

Despite being an important way for clinicians to protect their patients from becoming infected with HIV, PrEP continues to be underused.